Articles from PHIL Inc.

PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx, Harrow’s new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow’s branded ophthalmic portfolio from one destination within the electronic medical record (EMR) systems they already use, with built-in patient services, ECP support, and affordability programs.

PHIL Inc., a direct-to-patient (DTP) and digital hub platform for pharmaceutical manufacturers, today released a new report, The DTP Breakthrough: A Deep Dive on Pharma's Direct-to-Patient Next Generation. The exclusive research from a survey of 74 life sciences leaders across the United States, sourced by an independent third-party research panel, captures the current state of direct-to-patient adoption and the strategic and operational shifts set to define the industry’s next phase of innovation. The findings build on foundational research from earlier in the year that uncovered what patients and providers want from these programs.

PHIL, the technology-powered patient access platform, today announced the launch of New Day™ Direct-to-Patient program in partnership with Evolved Health. The program delivers a first-of-its-kind prescription topical emulsion spray for mild to severe atopic dermatitis directly to patients.

PHIL Inc. today announced a significant expansion of its cash dispense capabilities, a major strategic investment that positions the company to continue serving the rapidly growing direct-to-patient (DTP) market, helping pharmaceutical companies get medications in the hands of patients at scale.

Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI™, the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia.

Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with RedHill Biopharma (Nasdaq: RDHL) (‘RedHill’) to make its medication Talicia® (omeprazole magnesium, amoxicillin, and rifabutin) available via the PhilRx Patient Access Platform.

Phil Inc., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform. Teva’s Digihaler system is the first and only smart inhaler system that can provide objective inhaler data to help patients and their doctors have informed treatment discussion in support of asthma management.

Phil Inc., a patient access platform company that revolutionizes life science product commercialization with technology to improve patient prescription access, today announced an exclusive partnership with Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization. Through the strategic partnership, Phil will serve as Syneos Health’s hub partner, creating an end-to-end commercialization solution for life sciences organizations to ensure patients can seamlessly start and adhere to therapy and receive and refill medicines quickly, easily and affordably.